ALTSTATION.IO

AMETEK, Inc. (AME) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$231.02

Change

+0.54%

Market Cap

$53.35B

Avg Volume

1.4M

Company Overview

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices. Their products serve a wide array of industries, including aerospace, pharmaceuticals, and food and beverage. Key offerings include advanced instruments for process control, analytical tools for testing, power monitoring devices, and components for medical applications. With a global presence, they cater to customers looking for high-precision and reliable instrumentation and automation solutions.

AMETEK is a market leader in the Specialty Industrial Machinery sector. Their competitive edge lies in their diverse product offerings and strong brand reputation, particularly in high-tech industries. However, they face challenges from competitors like Honeywell and Siemens, who also operate in similar markets. The shift towards automation and advanced technologies could both boost AMETEK’s growth and heighten competition, depending on how effectively they adapt to evolving customer demands.

Currently, AMETEK is on a growth trajectory, evidenced by their recent acquisition of smaller technology firms to expand their capabilities. Their focus on innovation and high-margin products is reflected in their consistent revenue gains, showing a strong annual growth rate of around 9% over the past few years. Strategic investments in research and development are setting a solid foundation for continued expansion and market penetration moving forward.

Key Financials

Market Cap

$53.35B

Revenue

$7.40B

EBITDA

$2.36B

Gross Margin

36.4%

Profit Margin

20.0%

Revenue Growth

13.4%

Total Cash

$457.95M

Total Debt

$2.28B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

36.04

Forward P/E

26.56

Beta

1.04

52-Week High

$234.56

52-Week Low

$145.02

EPS

$6.41

50-Day Avg

$209.51

200-Day Avg

$189.47

Price/Book

4.99

Technical Analysis

Over the past 52 weeks, AMETEK, Inc. (AME) has demonstrated a strong upward trend, with the stock appreciating approximately 25.5% to its current price of $231.02. Key support is identified around the $180 level, where the stock found a base in June before resuming its upward trajectory. Resistance is evident near the $240 mark, reached in January 2023, which may serve as a potential barrier for further upside movement. The chart displays a series of higher lows and higher highs, indicating solid bullish momentum, especially over the last few weeks where the stock has maintained a consistent upward slope. Currently, the price sits near the upper range of its 52-week performance, suggesting upward pressure and a potential continuation of the trend, provided it navigates through resistance effectively. Overall, AME shows a robust bullish outlook in the current trading environment.

Recent News and Developments

Here’s a summary of the latest news and developments for AMETEK, Inc

(AME) stock in the past week:

Market Update

### AMETEK Reports Record Fourth Quarter and Full Year 2025 Results

AMETEK, Inc

announced record financial results for the fourth quarter and full year ended December 31, 2025, on February 3, 2026. Fourth-quarter sales reached a record $2.0 billion, a 13% increase over the fourth quarter of 2024. GAAP earnings were a record $1.73 per diluted share, while adjusted earnings also hit a record at $2.01 per diluted share, up 7% from the previous year’s fourth quarter. The company’s full-year 2025 sales rose to $7.40 billion, with increased net income and earnings per share compared to 2024.

Market Sentiment and Analyst Recommendations

Bull Case

AMETEK just posted record Q4 results with $2.0B in quarterly sales and 13% year-over-year growth, backed by $7.40B in full-year revenue. The LKC Technologies acquisition gives them a foothold in ophthalmic devices, a high-margin medical tech segment with structural tailwinds. Four major analysts raised price targets in one week, with DA Davidson and Truist both moving to $265 — that’s 15% upside from here. The company sits with $457.95M in cash against only $2.28B in debt, giving them firepower for more acquisitions without financial stress. At 36x P/E the multiple is steep, but 13.4% revenue growth justifies a premium to industrials peers, especially if they sustain mid-double-digit organic growth alongside accretive M&A.

Bear Case

That 36.04 P/E is the real problem. You’re paying premium valuation for a company that’s already at a 52-week high after a 25.5% run, leaving little margin for error. One analyst explicitly cited elevated valuation multiples as the reason for a Hold rating despite strong fundamentals — that’s a warning signal about consensus expectations. The LKC acquisition is unproven; ophthalmic devices are a new market for AMETEK and execution risk is real. Debt sits at $2.28B against $457.95M in cash, a 5:1 ratio that limits flexibility if organic growth slows or macro conditions deteriorate. If revenue growth decelerates below 10% or margins compress from integration costs, this stock gets repriced lower fast given how stretched the valuation already is.

What to Watch

Monitor Q1 2026 organic growth rates closely — if they fall below 10%, that’s a red flag that the 13.4% headline number was driven purely by LKC timing. Watch gross margin trends over the next two quarters as LKC integration costs hit the P&L. The $240 resistance level is critical; a break above it targets $250-$260, but failure to hold support around $225-$230 would signal momentum exhaustion. Track cash flow generation and whether management commits to debt reduction or signals more acquisition spending — that shapes the risk profile. Finally, listen to guidance on 2026 full-year growth rates during upcoming earnings calls; anything below 10% growth would contradict the bull thesis and likely trigger multiple compression.

Analyst Consensus

BUY

Based on 17 analyst opinions

Low Target

$208.00

Mean Target

$248.29

High Target

$274.00

Earnings and Financial Data

Sector

Industrials

Industry

Specialty Industrial Machinery

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$6.41

Dividend Yield

54.0%

Payout Ratio

19.4%

Frequently Asked Questions

Is AMETEK (AME) a good stock to buy?

Analysts recommend a “BUY” on AMETEK with a target price of $248.29, which suggests a potential upside from the current price of $231.02. With a solid market cap of $53.35 billion and a strong presence in the specialty industrial machinery industry, investor sentiment is positive.

What is AMETEK’s price target?

The current analyst price target for AMETEK is $248.29. This target represents approximately a 7.5% upside from the current trading price of $231.02.

Does AMETEK pay a dividend?

Yes, AMETEK offers a dividend yield of 54.0%. This is attractive for income-focused investors looking for a steady return on their investment.

What is AMETEK’s P/E ratio?

AMETEK has a P/E ratio of 36.04 and a forward P/E of 26.56. These valuations indicate that the stock is trading at a premium, reflecting optimistic growth expectations in the industrial sector.

What has been AMETEK’s price range over the last year?

AMETEK’s stock has traded between $145.02 and $234.56 over the past 52 weeks. This range highlights significant volatility but also the potential for growth in a recovering industrial sector.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.